Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIRSNASDAQ:BDSXNYSEAMERICAN:CCELNASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIRSAirSculpt Technologies$2.29-8.0%$4.36$2.24▼$9.20$134.14M1.69139,350 shs206,861 shsBDSXBiodesix$0.67-6.0%$0.89$0.64▼$2.04$97.81M1.1291,276 shs157,705 shsCCELCryo-Cell International$6.30-1.9%$0.00$5.75▼$9.50$50.78M0.5312,457 shs8,537 shsSERASera Prognostics$3.54-9.2%$4.66$3.50▼$12.36$119.55M0.89135,360 shs152,837 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIRSAirSculpt Technologies0.00%-13.26%-49.45%-58.36%-62.70%BDSXBiodesix0.00%-20.83%-15.51%-54.11%-53.15%CCELCryo-Cell International0.00%-4.26%+19.77%+19.77%+19.77%SERASera Prognostics0.00%-6.60%-16.51%-57.55%-61.10%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIRSAirSculpt Technologies1.2541 of 5 stars3.00.00.00.01.53.30.0BDSXBiodesix3.0473 of 5 stars3.53.00.00.03.42.50.6CCELCryo-Cell International3.3421 of 5 stars3.55.01.70.03.01.70.0SERASera Prognostics0.9837 of 5 stars0.03.00.00.03.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIRSAirSculpt Technologies 2.00Hold$5.00118.34% UpsideBDSXBiodesix 3.00Buy$2.95340.30% UpsideCCELCryo-Cell International 3.00Buy$8.5034.92% UpsideSERASera Prognostics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CCEL, AIRS, SERA, and BDSX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/4/2025CCELCryo-Cell InternationalMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.501/17/2025AIRSAirSculpt TechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $5.001/6/2025AIRSAirSculpt TechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $6.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIRSAirSculpt Technologies$180.35M0.74$0.09 per share25.15$1.46 per share1.57BDSXBiodesix$71.32M1.37N/AN/A$0.05 per share13.40CCELCryo-Cell International$31.34M1.62$0.52 per share12.09($1.33) per share-4.74SERASera Prognostics$77K1,552.63N/AN/A$2.21 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIRSAirSculpt Technologies-$4.48M-$0.15N/A∞N/A-4.13%2.22%0.90%4/28/2025 (Estimated)BDSXBiodesix-$52.15M-$0.35N/AN/AN/A-66.84%-275.79%-43.05%5/6/2025 (Estimated)CCELCryo-Cell International-$9.52M-$1.06N/A∞N/A-28.03%-42.06%7.06%N/ASERASera Prognostics-$36.24M-$0.99N/AN/AN/AN/A-51.73%-36.94%5/14/2025 (Estimated)Latest CCEL, AIRS, SERA, and BDSX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 million3/14/2025Q4 2024AIRSAirSculpt Technologies-$0.03-$0.08-$0.05-$0.09$38.99 million$39.18 million3/3/2025Q4 2024BDSXBiodesix-$0.07-$0.06+$0.01-$0.06$19.92 million$20.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIRSAirSculpt TechnologiesN/AN/AN/AN/AN/ABDSXBiodesixN/AN/AN/AN/AN/ACCELCryo-Cell International$1.0015.87%N/AN/A N/ASERASera PrognosticsN/AN/AN/AN/AN/ALatest CCEL, AIRS, SERA, and BDSX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/29/2025CCELCryo-Cell Internationalquarterly$0.2513.1%2/14/20252/14/20252/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIRSAirSculpt Technologies0.800.510.51BDSXBiodesix1.303.403.40CCELCryo-Cell InternationalN/A0.610.57SERASera PrognosticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIRSAirSculpt Technologies91.54%BDSXBiodesix20.96%CCELCryo-Cell International10.44%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipAIRSAirSculpt Technologies78.77%BDSXBiodesix69.20%CCELCryo-Cell International36.86%SERASera Prognostics15.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIRSAirSculpt Technologies24058.58 million12.56 millionOptionableBDSXBiodesix220145.98 million44.80 millionOptionableCCELCryo-Cell International908.06 million5.09 millionNot OptionableSERASera Prognostics12033.77 million28.44 millionOptionableCCEL, AIRS, SERA, and BDSX HeadlinesRecent News About These CompaniesSera Prognostics Earnings Call: Balancing Success and ChallengesMarch 21, 2025 | tipranks.comSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial ResultsMarch 21, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics Q4 2024 sees revenue drop, stock risesMarch 21, 2025 | uk.investing.comTD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)March 21, 2025 | markets.businessinsider.comSera Prognostics Full Year 2024 Earnings: Misses ExpectationsMarch 21, 2025 | finance.yahoo.comSera Prognostics (NASDAQ:SERA) Issues Quarterly Earnings ResultsMarch 20, 2025 | marketbeat.comSera Prognostics Plans Studies to Support US and EU Expansion; Firm’s Q4 Revenues Fall 41 PercentMarch 20, 2025 | 360dx.comSera Prognostics Q4 Revenues Fall 41 Percent While Firm Prepares for Commercial ExpansionMarch 20, 2025 | 360dx.comSera Prognostics beats Q4 revenue estimates, shares riseMarch 20, 2025 | investing.comSera Prognostics reports Q4 EPS (25c) vs. (25c) last yearMarch 20, 2025 | markets.businessinsider.comSera Prognostics appoints Jeff Elliott to Board, two members stepping downMarch 20, 2025 | markets.businessinsider.comSera Prognostics Reports 2024 Financial Results and Strategic PlansMarch 19, 2025 | tipranks.comSera Prognostics Inc (SERA) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comSera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue EstimatesMarch 19, 2025 | zacks.comSERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTSMarch 19, 2025 | prnewswire.comSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWNMarch 19, 2025 | prnewswire.comSera Prognostics (SERA) Expected to Announce Quarterly Earnings on WednesdayMarch 12, 2025 | marketbeat.comSera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025March 11, 2025 | prnewswire.comSera Prognostics To Present at TD Cowen 45th Annual Health Care ConferenceFebruary 21, 2025 | prnewswire.comSera Prognostics chief scientific officer sells shares for $27,090February 16, 2025 | msn.comSera Prognostics CFO sells $27,090 in stockFebruary 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockOracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term BuyBy Thomas Hughes | March 11, 2025View Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term BuySalesforce: An Early AI Opportunity With Long-Term PotentialBy Thomas Hughes | March 18, 2025View Salesforce: An Early AI Opportunity With Long-Term PotentialAirship AI: Why This AI Penny Stock Is Poised for a Big BreakoutBy Nathan Reiff | March 26, 2025View Airship AI: Why This AI Penny Stock Is Poised for a Big BreakoutOllie’s Bargain Outlet: Ollie’s Army Marching to New HighsBy Thomas Hughes | March 21, 2025View Ollie’s Bargain Outlet: Ollie’s Army Marching to New HighsCCEL, AIRS, SERA, and BDSX Company DescriptionsAirSculpt Technologies NASDAQ:AIRS$2.29 -0.20 (-8.03%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.29 0.00 (0.00%) As of 03/28/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. The company's body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.Biodesix NASDAQ:BDSX$0.67 -0.04 (-6.00%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.75 +0.08 (+11.34%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Cryo-Cell International NYSEAMERICAN:CCEL$6.30 -0.12 (-1.87%) Closing price 03/28/2025 04:10 PM EasternExtended Trading$6.29 -0.01 (-0.16%) As of 03/28/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.Sera Prognostics NASDAQ:SERA$3.54 -0.36 (-9.23%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.38 -0.16 (-4.55%) As of 03/28/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
